evotec.com (EVO): רווח נקי למניה ב-12 החודשים האחרונים

Evotec SE is developing a unique CRO platform by sharing risks and profits with its partners. Long-term contracts ensure a stable cash flow, while the recruitment of bioanalytics experts strengthens its scientific potential. This 12-month net income per share chart provided by GURU.Markets helps filter out market noise, while -0.60 shapes the current metric.

Evotec SE (EVO) expansion into the AI development and Just-Evotec biologics segment is creating long-term B2B streams that convert directly into final business profitability. This rolling annual earnings per share measures net income distributed across the total share issuance, allowing investors to assess real capital efficiency net of borrowing costs and operating expenses.